[Endocrinological aspects of hypophyseal XXXX ].

@entity4089 @entity5 @entity442 @entity2124 @entity2012 @entity977 @entity6392 @entity1176 @entity1943 @entity7961
Local expansion of @entity977 causes nonspecific symptoms, including hormone insufficiency, that may exist for years before diagnosis. Although they are more specific, symptoms of @entity7961 may also remain unrecognized and give rise to difficult diagnostic problems. @entity5 do not elicit specific endocrine symptoms, whether they secrete complete gonadotropins or their biologically inactive free subunits. @entity4089 is not due to @entity5 secretion in the majority of cases, including some with a @entity5 in the pituitary (compressive @entity4089 ). When @entity2012 is suspected, the unequivocal proof of excess @entity2124 secretion is not easy to obtain, due to intermittent @entity2124 secretion, both in normals and in acromegalics. The large variety of tests available for the etiological diagnosis of @entity6392 indicates the diagnostic difficulties that can be encountered. Corticotrope @entity977 may be minute, and ectopic corticotropin secretion may remain occult. But on the other hand, the quality of the diagnostic tools available improves constantly. This includes new hormone measurements, such as @entity442 and its binding proteins, dynamic tests, selective pituitary blood drawing by inferior petrosal sinus catheterism, pituitary nuclear magnetic resonance imaging and @entity1943 -analogue scintiscan. In addition to the improving techniques of transphenoidal neurosurgery and pituitary radiotherapy, medical management of @entity977 remains a distinct possibility. Tumor hormone secretion can be controlled in some cases by drugs such as dopaminergic agents, @entity1943 analogues and @entity1176 analogues, which may also exert an antitumoral mass effect. Within the next few years we will be confronted with an increasing number of incidentally discovered @entity977 , due to the frequent use of high-resolution intracranial imaging.
